MAPT and Alzheimer disease: Given the projected increase of prevalence of both diabetes and AD over the next decades [68, 69], further studies are warranted to investigate the effects of metformin on AD development, its contribution to the increased risk of AD associated with T2DM and its therapeutic potential for tau-related neurodegenerative conditions.